Hualan Genetic Recombinant Anti-CTLA-4 Human Monoclonal Antibody Injection (Ipilimumab) Starting Clinical Trial
Hualan Genetic Recombinant
Anti-CTLA-4 Human Monoclonal Antibody Injection (Ipilimumab) Starting Clinical
Trial
On October 10, 2018, Hualan GeneticEngineering Co., Ltd. received the clinical approval document of "Recombinant
Anti-CTLA-4 Human Monoclonal Antibody Injection" issued by the State Drug
Administration, with the approval number of 2018L03080. According to the drug
registration procedure, Hualan Genetic Engineering Co., Ltd will organize and
implement clinical trials as soon as possible in accordance with the
requirements of the national drug clinical trials after obtaining the approval
documents for the above drug clinical trials, and will apply the product production
approval documents and GMP certificate after completing the clinical trials.
With the registered capital of RMB 100
million Yuan, Hualan Genetic Engineering Co., Ltd. was established in June
2013. In May 2014, the company obtained Pharmaceutical Production License and
devoted to the R&D and manufacturing of monoclonal antibodies, recombinanthuman coagulation factor, hormone drugs as well as novel vaccines.
Hualan GeneticEngineering Co., Ltd |
评论
发表评论